

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

258739US0PCT

SERIAL NO.

15/507361
New U.S. PCT Application
Based on PCT/JP03/03996

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Masaaki NAGASAWA, et al.

FILING DATE

Herewith

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO	01/83473	11/08/01	WO (with English abstract; equivalent of JP 2002-12592 - English abstract only)		NO
	AP	01/14366	03/01/01	WO (with English abstract)		NO
	AQ	00/50037	08/31/00	WO		NO
	AR	99/18959	04/22/99	WO		NO
	AS					
	AT					
	AU					
	AV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AW	
	AX	
	AY	
	AZ	

☐ Additional References sheet(s) attached

Examiner

Date Considered 2/16/06

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 258739US0PCT		SERIAL NO. 10/507,361	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Masaaki NAGASAWA, et al.			
				FILING DATE September 20, 2004		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	2003/0236411	12/25/03	NAGASAWA, Masaaki et al. (US Serial No. 10/380,158)			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AB	54-141783	11/05/79	JP (with English abstract)			NO
	AC	94 27988	12/08/94	WO			NO
	AD	61-50978	03/13/86	JP (with English abstract)			NO
	AE	64-6270	01/10/89	JP (with English abstract)			NO
	AF	61-22079	01/30/86	JP (with English abstract)			NO
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AG	ANDO, Takashi et al. "1. Study of the Treatment of Gastric Ulcer Considering the Characteristics of Genetic Polymorphism of the Metabolic Enzyme CYP2C19", Gastric Secretion Research, vol. 34, pages 39-40, with full English translation 2002					
	AH	SHIMATANI, Tomohiko et al. "1. Are Proton Pump Inhibitors the Most Potent Gastric Acid Secretion Inhibitors?", Gastric Secretion Research, vol. 34, pages 99-103, with full English translation 2002					
	AI	KODAJRA, Junichi et al. "2. Relation between Acid Secretion Inhibition Effect of PPIs and CYP2C19 Genetic Polymorphisms in H. pylori-Negative Healthy Volunteers", Gastric Secretion Research, vol. 34, pages 105-108, with full English translation 2002					
	AJ	SAITO, Hisato et al. "3. Acid Secretion Inhibition Effect of PPI at an Initial Stage of Administration (in the Case of CYP2C19EM)", Gastric Secretion Research, vol. 34, pages 109-112, with full English translation 2002					
	AK	ISHIZAKI, Takashi. "What do the Latest Findings in Clinical Pharmacology Say about Choosing the Right PPI?", Nikkei Medical, vol. 7, pages 174-175, with full English translation 2001					
	AL	ANDERSSON, Tommy. "Pharmacokinetics, Metabolism and Interaction of Acid Pump Inhibitors", Clin. Pharmacokinet, vol. 31, no. 1, pages 9-28 1996					
	AM	HORAI, Y. et al. "Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes", Aliment. Pharmacol. Ther., vol. 15, pages 793-803 2001					
	AN	KRUSEKOPF, S. et al. "Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line", Xenobiotica, vol. 27, no. 1, pages 1-9 1997					
	AO	FURUTA, Takahisa et al. "Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer", Annals of Internal Medicine, vol. 129, no. 12, pages 1027-1030 1998					
	AP	FURUTA, Takahisa et al. "Effect of Genotypic Differences in CYP2C19 Status on the Cure Rates for Gastroesophageal Reflux Disease by Lansoprazole", Gastroenterology, vol. 120, suppl. 1, page A-432, #2203 2001					
	AQ	PARK, Soo-Heon et al. "Effect of CYP2C19 Polymorphism on Rabeprazole Induced Nocturnal Acid Breakthrough", Gastroenterology, vol. 120, suppl. 1, page A-435, #2219 2001					
	AR	SAGAR, M. et al. "Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment", Aliment. Pharmacol. Ther., vol. 13, pages 453-458 1999					
	AS	KOKUFU, T. et al. "Effects of lansoprazole on pharmacokinetics and metabolism of theophylline", Eur. J. Clin. Pharmacol., vol. 48, pages 391-395 1995					
	AT	DIAZ, Dominique et al. "Omeprazole is an Aryl Hydrocarbon-like Inducer of Human Hepatic Cytochrome P450", Gastroenterology, vol. 99, pages 737-747 1990					
Examiner				Date Considered 2/16/06			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							